Solving Public Health Problems

Yellow Fever (YF)

We Need Your Specimens to Improve Public Health

We’d like to collaborate with you! You can support public health by depositing your isolates in CDC’s Arbovirus Reference Collection (ARC). The ARC offers long-term curation, maintenance, and distribution of valuable isolates. Contact the ARC staff about depositing your isolates for long-term curation, maintenance, and distribution.

If you need reagents, visit our Arboviral Reagent Ordering System.

Even with an effective vaccine, YF continues to be a public health problem:

  • International exportation of YF occurred during the 2016 YF outbreaks in Angola and Democratic Republic of the Congo.
  • Limited YF global vaccine supply

YF Public Health Problem #1

  • Address the need for a readily available, standardized, YF serological testing kit that can be used in resource-limited countries
  • Address the need for rapid YF diagnosis to quickly and effectively mobilize YF vaccine stocks in the event of an outbreak


Yellow Fever Virus MAC-HD Kit

Easy-to-use Yellow Fever Virus MAC-HD Kit. Credit: CDC

Developed by Ms. Jane Basile at CDC1

Easy-to-use YFV MAC-HD kit

  • Tests for IgM antibodies to YF
  • Includes pre-measured reagents and ready-to-use plates
  • Allows for assay completion in 3.5 hours
  • Tests 8 or 24 serum samples per plate
  • Kit (see photo) used by African and South American regional reference and national laboratories where YF is present.

Important benefits to public health

  • Kit allows for rapid (half-day) YF serological diagnosis, critical during a YF outbreak to quickly and effectively mobilize vaccine stocks
  • Kit format allows for standardization of YF serological testing within and across laboratories performing the test

ARC contribution

  • Inactivated YF antigen
  • Normal antigen
  • YF positive control
  • Conjugate

YF Public Health Problem #2

Address the need to differentiate between individuals infected with wild-type YF and individuals experiencing YF vaccination adverse events during YF outbreak vaccination campaigns

  • Wild-type YF infection and YF vaccination adverse events are clinically and serologically indistinguishable.
Illustration of LNA and DNA monomers

The YF 17D-specific real-time PCR assay uses Locked-nucleic acid (LNATM) bases to distinguish single nucleotide difference

YF 17D real-time PCR assay

Developed by Dr. Holly Hughes at CDC2

YF 17D-specific real-time PCR assay

  • Distinguishes between wild-type YF and 17D (vaccine) strains
    • Wild-type and 17D YF strains are genetically different by <10 nucleotides
  • Uses Locked-nucleic acid (LNA™) bases capable of distinguishing single nucleotide differences
    • Highly specific
    • Incorporated into probe

Important benefits to public health

Differentiation between wild-type YF infection and YF vaccination adverse events during a YF outbreak aids in:

  • Determining the nature and extent of the outbreak
  • Decision-making by clinicians and public health officials
  • Monitoring people during outbreak vaccination campaigns for vaccination adverse events

ARC contribution

  • 17 different isolates of YF virus
  • YF positive RNA controls

Mayaro (MAY)

Emerging mosquito-borne arboviral disease

  • Sporadic outbreaks in South and Central America – potential for urban outbreaks
  • No vaccine available

MAY Public Health Problem

Address the need to prepare for future MAY outbreaks by generating and making available MAY-specific reagents produced from the most currently circulating MAYV strain/genotype.

  • Currently circulating genotype – Genotype L

Acquisition, propagation, and generation of MAYV genotype L

  • Received from Mr. Jeremy Lederman at CDC
  • Propagation of MAYV genotype L
    • MAYV stock and working seeds produced according to ARC QC guidelines.
  • Generation of MAYV genotype L positive RNA controls
    • MAYV RNA generated for molecular test development and research. RT-qPCR assay developed using MAYV genotype L primers and RNA.

Important benefits to public health

Aedes aegypti mosquito

Aedes aegypti mosquitoes spread several arboviruses. Credit: CDC, James Gathany

Having MAYV genotype L reagents readily available for distribution to both internal and external laboratorians and researchers aids in:

  • Faster public health response in the event of an emerging MAY outbreak
  • Timeliness of MAYV-related research performed to address an emerging MAY outbreak and to further enhance knowledge of MAYV.
    • Epidemiological studies
    • Vaccine and therapeutic studies

ARC contribution

  • Distribution of:
    • ARC QC-tested MAYV genotype L
    • MAYV genotype L positive RNA controls

1 Publication: Development and validation of an ELISA kit (YF MAC-HD) to detect IgM to yellow fever virus. Basile AJ, Goodman C, Horiuchi K, Laven J, Panella AJ, Kosoy O, Lanciotti RS, Johnson BW. 2015. J Virol Methods, 225: 41-8.

2 Publication: Development of a Real-Time Reverse Transcription-PCR Assay for Global Differentiation of Yellow Fever Virus Vaccine-Related Adverse Events from Natural Infections. Hughes HR, Russell BJ, Mossel EC, Kayiwa J, Lutwama J, Lambert AJ. 2018. J Clin Micro, 56(6): e00323-18.